BioWorld

April 16, 2007

Senate HELP Panel To Review Comprehensive FDA Measure

WASHINGTON - Wide-ranging FDA legislation is scheduled for Senate review on Wednesday, but notably, the bill does not include a provision related to follow-on biologics. (BioWorld Today) Read More

Dyax Gets Boost From Positive Phase III Data Of DX-88 In HAE

In Down's, A Narrow Solution To A Broad Learning Problem

Novelos' Financing To Garner $15M For Lung Cancer, Hep C

Clinic Roundup

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Dec. 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 10, 2025.

Epigenetic technology could eliminate misfolded prion proteins

BioWorld Science

The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Brenig Therapeutics discovers new LRRK2 inhibitors

BioWorld Science

Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...